Valdes Ana M
Department of Twin Research and Genetic Epidemiology, St Thomas' Hospital Campus, Kings College London, Lambeth Palace Rd, London, SE1 7EH, UK.
Per Med. 2010 Jan;7(1):49-63. doi: 10.2217/pme.09.68.
Osteoarthritis is the most common joint disorder and its prevalence is expected to climb as the age of the population increases. A hindrance to the development of disease-modifying drugs has been the inability to identify individuals who will rapidly progress towards severe disease. The principles of personalized medicine can be used to identify such individuals, which will enable the efficacy of disease-modifying drugs to be tested. Our current knowledge regarding the molecular pathogenesis of osteoarthritis indicates that there are several molecules that are candidates for therapeutic intervention and for which genetic variation affects disease risk and hence, they may be used in personalized medicine. Recent developments on the genetics of osteoarthritis from human association studies and animal models are discussed in this context.
骨关节炎是最常见的关节疾病,随着人口老龄化,其患病率预计还会攀升。疾病修饰药物研发的一个障碍是无法识别那些会迅速发展为严重疾病的个体。个性化医疗的原则可用于识别这类个体,这将有助于对疾病修饰药物的疗效进行测试。我们目前对骨关节炎分子发病机制的了解表明,有几种分子是治疗干预的候选对象,其基因变异会影响疾病风险,因此可用于个性化医疗。本文将在这一背景下讨论人类关联研究和动物模型在骨关节炎遗传学方面的最新进展。